• Underwriting Agreement executed overnight on 24-25 February 2026
• Termination events disclosed in Prospectus dated 30 March 2026
• Company confirms Underwriting Agreement remains in full effect

Rhythm Biosciences Ltd (RHY) has responded to an ASX query letter regarding its underwriting agreement for the exercise of listed options RHYO. The company confirmed the Underwriting Agreement was executed overnight on 24-25 February 2026, and the termination events were disclosed in the Prospectus dated 30 March 2026. RHY acknowledged that the summary of termination events in the 25 February 2026 announcement was incomplete, but stated the termination provisions in the Prospectus accurately reflect the executed Underwriting Agreement. The company also confirmed the Underwriting Agreement remains in full effect, with a Shortfall Notice issued on 2 April 2026 in accordance with the agreement. RHY outlined the steps it took to ensure disclosure was accurate, including reviewing the announcement in line with its Continuous Disclosure Policy, though it admitted some termination provisions were inadvertently overlooked in the initial summary. The company confirmed it is in compliance with the Listing Rules, particularly Listing Rule 3.1.